NASDAQ:RIGL Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free RIGL Stock Alerts $0.99 -0.20 (-16.77%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$0.98▼$1.1350-Day Range$1.05▼$1.5752-Week Range$0.71▼$1.96Volume3.54 million shsAverage Volume1.33 million shsMarket Capitalization$174.05 millionP/E RatioN/ADividend YieldN/APrice Target$5.81 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Rigel Pharmaceuticals alerts: Email Address Rigel Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside485.8% Upside$5.81 Price TargetShort InterestHealthy2.95% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.44Based on 13 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.05) to $0.05 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.76 out of 5 starsMedical Sector614th out of 905 stocksPharmaceutical Preparations Industry283rd out of 422 stocks 3.3 Analyst's Opinion Consensus RatingRigel Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageRigel Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Rigel Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.95% of the outstanding shares of Rigel Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRigel Pharmaceuticals has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rigel Pharmaceuticals has recently increased by 3.19%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRigel Pharmaceuticals does not currently pay a dividend.Dividend GrowthRigel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RIGL. Previous Next 1.4 News and Social Media Coverage News SentimentRigel Pharmaceuticals has a news sentiment score of -0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Rigel Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest12 people have searched for RIGL on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Rigel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.04% of the stock of Rigel Pharmaceuticals is held by insiders.Percentage Held by Institutions66.23% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rigel Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rigel Pharmaceuticals are expected to grow in the coming year, from ($0.05) to $0.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rigel Pharmaceuticals is -6.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rigel Pharmaceuticals is -6.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Rigel Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.Don't miss out on the "next Ozempic" >>> About Rigel Pharmaceuticals Stock (NASDAQ:RIGL)Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Read More RIGL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RIGL Stock News HeadlinesMay 8, 2024 | finanznachrichten.deRigel Pharmaceuticals, Inc.: Rigel Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed on Rigel’s Consistent Performance and Growth ProspectsMay 8, 2024 | Behind the Markets (Ad)BREAKING – Pentagon to Spend $20 Billion on “Distributed AI”BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.May 8, 2024 | finance.yahoo.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comRigel Pharmaceuticals Inc (RIGL) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves ...May 7, 2024 | investorplace.comRIGL Stock Earnings: Rigel Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024May 7, 2024 | markets.businessinsider.comRigel Pharmaceuticals Inc. Q1 Loss decreases, but misses estimatesMay 7, 2024 | prnewswire.comRigel Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | Behind the Markets (Ad)BREAKING – Pentagon to Spend $20 Billion on “Distributed AI”BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.May 7, 2024 | markets.businessinsider.comRigel Pharmaceuticals is about to announce earnings — here's what Wall Street expectsMay 5, 2024 | americanbankingnews.comRigel Pharmaceuticals (RIGL) to Release Quarterly Earnings on TuesdayApril 30, 2024 | prnewswire.comRigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business UpdateApril 10, 2024 | prnewswire.comRigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)April 4, 2024 | prnewswire.comRigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & LymphomaMarch 16, 2024 | finance.yahoo.comRIGL Apr 2024 3.000 callMarch 12, 2024 | finanznachrichten.deRigel Pharmaceuticals, Inc.: Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical OfficerMarch 12, 2024 | markets.businessinsider.comRigel Pharma Names Rojkjaer EVP, Chief Medical OfficerMarch 12, 2024 | prnewswire.comRigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical OfficerMarch 7, 2024 | finance.yahoo.comRigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the YearMarch 7, 2024 | insidermonkey.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | barrons.comRigel Pharmaceuticals Inc.March 6, 2024 | stockhouse.comRigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 6, 2024 | benzinga.comRigel Pharmaceuticals: Q4 Earnings InsightsMarch 6, 2024 | markets.businessinsider.comRigel Pharmaceuticals Inc. Q4 Earnings SummaryMarch 6, 2024 | msn.comRigel Pharmaceuticals GAAP EPS of $0.00 beats by $0.02, revenue of $35.8M beats by $2.39MMarch 6, 2024 | finance.yahoo.comOwning 47% shares,institutional owners seem interested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL),March 6, 2024 | finance.yahoo.comQ4 2023 Rigel Pharmaceuticals Inc Earnings CallSee More Headlines Receive RIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/08/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:RIGL CUSIP76655960 CIK1034842 Webwww.rigel.com Phone(650) 624-1100Fax650-624-1101Employees147Year Founded1996Price Target and Rating Average Stock Price Target$5.81 High Stock Price Target$15.00 Low Stock Price Target$1.25 Potential Upside/Downside+461.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,090,000.00 Net Margins-21.47% Pretax Margin-21.47% Return on EquityN/A Return on Assets-21.21% Debt Debt-to-Equity RatioN/A Current Ratio1.86 Quick Ratio1.76 Sales & Book Value Annual Sales$116.88 million Price / Sales1.55 Cash FlowN/A Price / Cash FlowN/A Book Value($0.16) per share Price / Book-6.47Miscellaneous Outstanding Shares175,400,000Free Float159,548,000Market Cap$181.54 million OptionableOptionable Beta1.06 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Raul R. Rodriguez (Age 63)President, CEO & Director Comp: $1.17MMr. Dean L. Schorno CPA (Age 61)Executive VP & CFO Comp: $736.72kMr. Raymond J. Furey J.D. (Age 56)Executive VP, General Counsel & Corporate Secretary Comp: $683kMr. David A. Santos (Age 61)Executive VP & Chief Commercial Officer Comp: $737.18kMs. Julie PatelSenior VP of Human ResourcesDr. Esteban S. Masuda (Age 62)Executive Vice President of Research Comp: $537.21kMr. Joseph Lasaga (Age 49)Executive VP & Chief Business Officer Dr. Lisa Rojkjaer M.D. (Age 58)Executive VP & Chief Medical Officer Mr. Tarek SallamVice President of MarketingMore ExecutivesKey CompetitorsMerrimack PharmaceuticalsNASDAQ:MACKEmergent BioSolutionsNYSE:EBSRegulus TherapeuticsNASDAQ:RGLSXOMANASDAQ:XOMAVerastemNASDAQ:VSTMView All CompetitorsInstitutional OwnershipRussell Investments Group Ltd.Sold 28,100 shares on 5/8/2024Ownership: 0.067%SG Americas Securities LLCSold 27,484 shares on 5/7/2024Ownership: 0.013%GSA Capital Partners LLPSold 47,512 shares on 5/3/2024Ownership: 0.787%BNP Paribas Financial MarketsBought 49,223 shares on 5/1/2024Ownership: 0.144%Principal Financial Group Inc.Sold 81,819 shares on 4/29/2024Ownership: 0.035%View All Institutional Transactions RIGL Stock Analysis - Frequently Asked Questions Should I buy or sell Rigel Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RIGL shares. View RIGL analyst ratings or view top-rated stocks. What is Rigel Pharmaceuticals' stock price target for 2024? 4 equities research analysts have issued 12-month target prices for Rigel Pharmaceuticals' stock. Their RIGL share price targets range from $1.25 to $15.00. On average, they expect the company's share price to reach $5.81 in the next year. This suggests a possible upside of 485.8% from the stock's current price. View analysts price targets for RIGL or view top-rated stocks among Wall Street analysts. How have RIGL shares performed in 2024? Rigel Pharmaceuticals' stock was trading at $1.45 on January 1st, 2024. Since then, RIGL shares have decreased by 31.6% and is now trading at $0.9923. View the best growth stocks for 2024 here. When is Rigel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024. View our RIGL earnings forecast. How were Rigel Pharmaceuticals' earnings last quarter? Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced its quarterly earnings data on Tuesday, May, 7th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.02. The biotechnology company had revenue of $29.53 million for the quarter, compared to analysts' expectations of $31.28 million. During the same quarter last year, the company posted ($0.08) earnings per share. What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO? 6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among the company's employees. What other stocks do shareholders of Rigel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI). Who are Rigel Pharmaceuticals' major shareholders? Rigel Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include GSA Capital Partners LLP (0.79%), Los Angeles Capital Management LLC (0.34%), BNP Paribas Financial Markets (0.14%), Russell Investments Group Ltd. (0.07%), Principal Financial Group Inc. (0.04%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include David A Santos, Dean L Schorno and Raul R Rodriguez. View institutional ownership trends. How do I buy shares of Rigel Pharmaceuticals? Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RIGL) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarningsWatch this FREE trading tutorial while it’s still availableInvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward Press[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.